# A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

> **NCT00549666** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Lurasidone 40 mg
- **DRUG:** Placebo 40 mg
- **DRUG:** Ortho Tri-Cyclen

## Key facts

- **NCT ID:** NCT00549666
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2011-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00549666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00549666, "A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00549666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*